Harbaugh brings more than 25 years of experience in finance, business and strategy, and operations management. As CFO, Harbaugh will oversee all financial aspects of the company, including accounting, financial planning and analysis, tax and treasury. He will report directly to the company's CEO, J. Christopher Barry, and serve as a member of the NuVasive global executive team.
"With his financial, operational and leadership experience at large, global companies, Matt is an excellent fit for NuVasive as we enter our next stage of growth," said Barry. "We are confident that his skills and expertise will help us continue building and transforming the organization and execute our five-year strategic plan."
Most recently, Harbaugh served as president of the specialty generics business at Mallinckrodt plc. Prior to that, he was Mallinckrodt's CFO for more than five years. During his tenure as CFO, he oversaw the company's accounting, treasury and tax functions, as well as information technology, procurement and facilities. Harbaugh previously held a variety of financial management positions at Covidien Pharmaceuticals, which was spun-off from Covidien plc as Mallinckrodt plc in July 2013. Harbaugh joined Covidien in 2007 and served in several finance and leadership roles, including as CFO and interim president of Covidien Pharmaceuticals. Harbaugh's prior experience includes nearly 10 years at Monsanto Company, where he held various roles in investor relations and finance as well as two ex-patriate positions.
Harbaugh holds a Bachelor of Science degree in Business Administration from Saint Louis University and an Executive Master of Business Administration degree from Kellogg School of Management at Northwestern University. He was named "Best CFO" in Institutional Investor's 2017 All-America Executive Team.
Asarpota has agreed to remain with the company in an advisory role until May 2020 to assist in the transition of duties and thereafter to provide ongoing consulting services until September 2020. The company thanks Asarpota for his commitment and contributions to NuVasive.
NuVasive reaffirms its annual financial guidance for full-year 2019 as previously issued in its earnings release on October 30, 2019.